Synthego is a genome engineering company that enables access to CRISPR to accelerate life science research and development.
Synthego has raised $200.0M in total funding. The most recent round was Series E. The last funding was announced in February 2022.
Synthego's investors include RA Capital Management, Menlo Ventures, Wellington Management, Founders Fund, 8VC.
Synthego is headquartered in Redwood City, United States.
Synthego is a genome engineering company that enables access to CRISPR to accelerate life science research and development.
Synthego is at the Series E stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Synthego — Funding & Investors." VCBacked, February 17, 2022, https://www.vcbacked.co/company/synthego. Accessed August 15, 2026.
VCBacked. (2022). Synthego — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/synthego
{{cite web |title=Synthego — Funding & Investors |url=https://www.vcbacked.co/company/synthego |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated